Ling Zeng, J.D., joined Dicerna as Chief Legal Officer and Secretary in September 2020. She brings to her role more than 20 years of broad and deep experience in biopharmaceutical law and global drug development and has held multiple leadership positions in North America, Europe and the Asia-Pacific region.
Ms. Zeng joined Dicerna from Novartis AG where she served as Deputy Head of the Legal M&A Group responsible for mergers and acquisitions (M&A). Prior to Novartis, Ms. Zeng held several senior-level positions at Bausch Health Companies, Inc., most recently as Vice President and General Counsel for Europe, the Middle East and Africa (EMEA), where she was responsible for EMEA legal matters in over 30 countries, and provided counsel on business development efforts, commercial operations, compliance, regulatory and IP strategies, and M&A transactions and integrations. Earlier in her career, Ms. Zeng was an associate at Cleary, Gottlieb, Steen & Hamilton in New York. Ms. Zeng was a Research Scientist prior to beginning her legal career.
Ms. Zeng earned her Juris Doctor, cum laude, from Georgetown University, a Master of Science degree in biophysics from Brandeis University, and a Bachelor of Science degree in physics from Peking University.
How do I contact Ling Zeng?
Has Ling Zeng been buying or selling shares of Dicerna Pharmaceuticals?
Ling Zeng has not been actively trading shares of Dicerna Pharmaceuticals over the course of the past ninety days. Most recently, Ling Zeng sold 1,334 shares of the business's stock in a transaction on Friday, September 17th. The shares were sold at an average price of $21.47, for a transaction totalling $28,640.98. Learn More on Ling Zeng's trading history.
Who are Dicerna Pharmaceuticals' active insiders?
